摘要
目的 阿托伐他汀联合曲美他嗪治疗冠心病的临床疗效。方法 76例冠心病患者,按照随机数表法分为观察组与对照组,各38例。对照组患者应用曲美他嗪治疗,观察组患者应用曲美他嗪联合阿托伐他汀治疗。比较两组治疗效果、治疗前后心功能指标[左室射血分数(LVEF)、左室舒张末期内径(LVEDD)、左室收缩末期内径(LVESD)]变化情况、不良反应发生情况。结果 观察组治疗总有效率94.7%高于对照组的78.9%,差异有统计学意义(P<0.05)。治疗后,两组LVEF、LVEDD、LVESD水平均优于本组治疗前,且观察组LVEF、LVEDD、LVESD水平分别为(48.3±1.5)%、(45.7±2.2)mm、(34.9±1.9)mm,均优于对照组的(45.6±2.1)%、(50.7±2.5)mm、(42.4±1.3)mm,差异均有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论 阿托伐他汀联合曲美他嗪治疗冠心病可明显提高临床治疗效率,改善患者的心功能指标,且不会增加不良反应发生率,可临床推广应用。
Objective To analyze the clinical efficacy of atorvastatin combined with trimetazidine in the treatment of coronary heart disease. Methods A total of 76 patients with coronary heart disease were divided into observation group and control group according to the random numerical table, with 38 cases in each group.Patients in the control group were treated with trimetazidine, and patients in the observation group were treated with trimetazidine combined with atorvastatin. Both groups were compared in terms of therapeutic effect, cardiac function indexes [left ventricular ejection fraction(LVEF), left ventricular end-diastolic diameter(LVEDD), left ventricular end-systolic diameter(LVESD)] before and after treatment, and the occurrence of adverse reactions.Results The total effective rate 94.7% of the observation group was higher than 78.9% of the control group, and the difference was statistically significant(P<0.05). After treatment, the levels of LVEF, LVEDD and LVESD in the two groups were better than those before treatment in this group, and the levels of LVEF, LVEDD and LVESD in the observation group were(48.3±1.5)%,(45.7±2.2) mm, and(34.9±1.9) mm, which were better than(45.6±2.1)%,(50.7±2.5) mm, and(42.4±1.3) mm in the control group. All the differences were statistically significant(P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05). Conclusion Atorvastatin combined with trimetazidine in the treatment of coronary heart disease can significantly improve the clinical treatment efficiency, improve the patient’s cardiac function index,and will not increase the incidence of adverse reactions, which can be clinically popularized and applied.
作者
孙瑛
SUN Ying(Yingkou Economic and Technological Development Zone Central Hospital(Yingkou Sixth People's Hospital),Yingkou 115007,China)
出处
《中国现代药物应用》
2022年第10期125-127,共3页
Chinese Journal of Modern Drug Application
关键词
阿托伐他汀
曲美他嗪
冠心病
Atorvastatin
Trimetazidine
Coronary heart disease
